Literature DB >> 14615911

Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).

J Christodoulou1, C Schoch, S Schnittger, T Haferlach.   

Abstract

We report on a 21-year-old man with a mediastinal germ cell tumor (MGCT) who developed a myelodysplastic syndrome (MDS) (refractory anemia with ringed sideroblasts, RARS) 10 months after the start of successful treatment with cisplatin, etoposide, ifosfamide, and paclitaxel. A very rare early occurrence of a therapy-related MDS was suspected. Cytogenetic analysis of the bone marrow revealed an aberrant karyotype, showing a deletion in 12p, an isochromosome 5p, as well as gain of an isochromosome 12p. Isochromosome 12p is a specific aberration frequently observed in MGCT. It also was described in patients who developed hematological transformation of a mediastinal germ cell tumor. In this report the association between mediastinal germ cell tumors and hematological malignancies including the possibility of a common genetic origin is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615911     DOI: 10.1007/s00277-003-0787-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13).

Authors:  Christian Paar; Gabriele Herber; Daniela Voskova; Michael Fridrik; Herbert Stekel; Jörg Berg
Journal:  Mol Cytogenet       Date:  2013-09-30       Impact factor: 2.009

2.  Paclitaxel Induced MDS and AML: A Case Report and Literature Review.

Authors:  Udit Bhaskar Bhatnagar; Daulath Singh; Alexy Glazyrin; Jill Moormeier
Journal:  Case Rep Oncol Med       Date:  2016-02-29

3.  Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.

Authors:  Jessica T Leonard; Philipp W Raess; Jennifer Dunlap; Brandon Hayes-Lattin; Jeffrey W Tyner; Elie Traer
Journal:  J Hematol Oncol       Date:  2016-03-31       Impact factor: 17.388

4.  Mediastinal Germ Cell Tumor-associated Histiocytic Proliferations Treated With Thalidomide Plus Chemotherapy Followed by Alemtuzumab-containing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.

Authors:  Li-Hua Fang; Li-Sun Shih; Pei-Ing Lee; Wei-Ting Chen; Rong-Long Chen
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.